Peptide Initiative

Peptides · Peptide comparison

Relaxin-2 (Serelaxin) vs Thymosin Beta-4

Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeRelaxin-2 (Serelaxin)30–30 mcg/kg/dayThymosin Beta-42–5 mg
FrequencyRelaxin-2 (Serelaxin)Once dailyThymosin Beta-4Twice weekly
AdministrationRelaxin-2 (Serelaxin)Intravenous (IV) infusionThymosin Beta-4Subcutaneous injection
Cycle lengthRelaxin-2 (Serelaxin)8-12 weeksThymosin Beta-48-12 weeks
Onset speedRelaxin-2 (Serelaxin)Moderate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelRelaxin-2 (Serelaxin)Limited human trialsThymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Cardiovascular Function

Relaxin-2 (Serelaxin)72%
Thymosin Beta-4No recorded rating

Heart Failure Support

Relaxin-2 (Serelaxin)68%
Thymosin Beta-4No recorded rating

Acute Medical Management

Relaxin-2 (Serelaxin)64%
Thymosin Beta-4No recorded rating

Wound Healing

Relaxin-2 (Serelaxin)No recorded rating
Thymosin Beta-495%

Inflammation Reduction

Relaxin-2 (Serelaxin)No recorded rating
Thymosin Beta-488%

Tissue Regeneration

Relaxin-2 (Serelaxin)No recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Relaxin-2 (Serelaxin)

Molecular formula
C256H408N74O74S8
Molecular weight
5,963 Da (Daltons)
Half-life
Varies by route of administration
Bioavailability
Varies by route of administration
CAS number
See PubChem for identifiers

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Relaxin-2 (Serelaxin)

Intravenous

  • 30 mcg/kg/dayContinuous IV infusion · 48 hoursWeight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only.

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Relaxin-2 (Serelaxin)

Acute heart failure symptom management
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area [5][9].
Cardiovascular recovery and support
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area [2].
Hospital-based therapeutic interventions
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area [3][15].

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Relaxin-2 (Serelaxin)

Common

  • Hypotension (low blood pressure) - most common
  • Tachycardia (increased heart rate)
  • Headache
  • Nausea
  • Dizziness
  • Peripheral edema (swelling)
  • Increased creatinine levels
  • Hyperkalemia (high potassium)
  • Syncope (fainting)
  • Atrial fibrillation
  • Blood pressure checks every 2-4 hours during infusion
  • Kidney function (creatinine and eGFR)
  • Electrolytes, particularly potassium
  • Heart rate and cardiac rhythm
  • Urine output

Serious

  • Severe cardiovascular events

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Relaxin-2 (Serelaxin)

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. [3][5][9] Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. [11] Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response [12].

Contraindications

  • Severe hypotension or hemodynamic instability
  • Pregnancy (despite relaxin's natural role)
  • Acute kidney injury or severe renal dysfunction
  • Recent myocardial infarction (within 7 days)
  • Uncontrolled arrhythmias

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Relaxin-2 (Serelaxin)

Choose Relaxin-2 (Serelaxin) if…

  • Acute heart failure symptom management
  • Cardiovascular recovery and support
  • Hospital-based therapeutic interventions

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation